Bad year at Cel­gene? For­get about it. CEO Mark Alles nabbed a big raise as com­pen­sa­tion gy­rat­ed to $16.2M

By all ac­counts, 2018 was a grim year for Cel­gene. Just months af­ter it $CELG was forced to scrap its $710 mil­lion drug GED-0301, the big biotech an­nounced that the FDA had hand­ed back its NDA for pipeline star ozan­i­mod. And the com­pa­ny’s pub­lic rep took a beat­ing through the year as its stock took a sick­en­ing plunge from over the $100 mark down to $62.43 in the De­cem­ber trough.

That per­for­mance — a dra­mat­ic de­cline in mar­ket cap of 38% — just ahead of Bris­tol-My­ers’ $74 bil­lion buy­out deal un­veiled on Jan­u­ary 3, val­ued at $102.43 a share, was worth a big hike in in­come for CEO Mark Alles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER